<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523731</url>
  </required_header>
  <id_info>
    <org_study_id>TV-003</org_study_id>
    <secondary_id>ACPs-CLI</secondary_id>
    <nct_id>NCT00523731</nct_id>
  </id_info>
  <brief_title>ACPs in Severe PAD/CLI by Direct Intramuscular Injection</brief_title>
  <official_title>A Study of Blood-Borne Autologous Angiogenic Cells Precursors Therapy in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TheraVitae Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TheraVitae Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study title: A Study of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients&#xD;
      with Critical Limb Ischemia ( ACPs-CLI )&#xD;
&#xD;
      Principle Investigator: Assoc.Prof. Pramook Mutirangura,M.D. Head of Division of Vascular&#xD;
      Surgery , Department of Surgery, Faculty of Medicine Siriraj Hospital , Mahidol University,&#xD;
      BKK,Thailand&#xD;
&#xD;
      Study objective : To determine the safety and efficacy of intramuscular injection of&#xD;
      blood-borne autologous ACPs in relieving symptoms of critical limb ischemia of patients&#xD;
      treated with maximal medical therapy and don't have intravascular or operative&#xD;
      revascularization option.&#xD;
&#xD;
      Study Design : A pilot study , a single center, a non-randomized, open-label trial.&#xD;
&#xD;
      Total expected no. of patients : 6 main selection criteria : A. Subjects will have one or&#xD;
      more clinical indications diagnostic of CLI such as: distal extremity pain at rest that&#xD;
      requires the subject to use analgesics for &gt;2 weeks; or peripheral ischemic ulcer(s); or&#xD;
      areas of gangrene ; or non-healing ischemic ulcers AND&#xD;
&#xD;
      B. Subjects will have one or more of the following hemodynamic indicators of severe&#xD;
      peripheral arterial occlusive disease:&#xD;
&#xD;
      I. Ankle brachial index &lt; 0.45 II. Toe brachial index &lt; 0.35 III. TcPO2 / TcO2 of &lt; 40 mmHg.&#xD;
      C. The subject is a poor candidate for standard revascularization treatment for peripheral&#xD;
      arterial disease, based on inadequate bypass conduit, or unfavorable anatomy D. Age 18 to 80&#xD;
      years&#xD;
&#xD;
      Investigational Product : At D-8 250 ml of blood drawn from the patients for production of&#xD;
      autologous EPCs or ACPs (VescellTM). On D0 ,at least 1.5 million ACPs with viability &gt;75 %&#xD;
      suspended in 30 ml sterile cell culture medium will be injected 1.5 cm deep and 1.5 apart by&#xD;
      a 23 -gauge needle into the gastrocnemius muscle of the leg chosen (ischemic leg) for&#xD;
      treatment. For injection planning a grid of 10X10 cm will be prepared and in each point 1 ml&#xD;
      of ACPs suspension will be injected.&#xD;
&#xD;
      The study consists of 4 periods: Screening ( D-14 to-9&amp; D-8,Treatment(D0),Acute Safety&#xD;
      follow-up (D1&amp;D2),Chronic follow-up (D30 &amp; D90)period ,total follow-up of each case is 3&#xD;
      months.&#xD;
&#xD;
      Evaluation criteria :&#xD;
&#xD;
      Safety : no.&amp; duration of adverse event &amp; serious adverse event Efficacy :Attenuate CLI&#xD;
      patients symptoms (Rest pain,Pain-free walking distance,Ulcer size &amp;Gangrene dimension and&#xD;
      intensity)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six patients with Critical Limb Ischemia (CLI) or severe Peripheral Arterial Disease(PAD)&#xD;
      will be enrolled, screened, treated with an injection of Blood-Borne Autologous Angiogenic&#xD;
      Cell Precursors(ACPs) in to gastrocnemius of the ischemic leg by intramuscular under regional&#xD;
      anesthesia. Following injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of ACPs intramuscular injection</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Attenuate CLI patients symptoms as</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rest pain</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain-free walking distance</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ulcer size</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gangrene dimension and intensity</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Obtain evidence for improvement of tissue perfusion due to ACPs injection</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of CLI patients hospitalization time.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease CLI patient amputation rate.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiogenic Cell Precursors (ACPs) or Vescell TM</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will have one or more clinical indications diagnostic of CLI such as: distal&#xD;
             extremity pain at rest that requires the subject to use analgesics for &gt;2 weeks; or&#xD;
             peripheral ischemic ulcer(s); or areas of gangrene ; or non-healing ischemic ulcers&#xD;
             AND&#xD;
&#xD;
          -  Subjects will have one or more of the following hemodynamic indicators of severe&#xD;
             peripheral arterial occlusive disease:&#xD;
&#xD;
               -  Ankle brachial index &lt; 0.45&#xD;
&#xD;
               -  Toe brachial index &lt; 0.35&#xD;
&#xD;
               -  TcPO2 / TcO2 of &lt; 40 mmHg.&#xD;
&#xD;
          -  The subject is a poor candidate for standard revascularization treatment options for&#xD;
             peripheral arterial disease, based on inadequate bypass conduit, or unfavorable&#xD;
             anatomy&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female&#xD;
&#xD;
          -  Informed consent obtained and consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having on angiography a meaningful supra popliteal occlusion that may relate&#xD;
             to symptoms of CLI.&#xD;
&#xD;
          -  Subjects, who in the opinion of the investigator, have a vascular disease prognosis&#xD;
             that indicates they would require a major amputation (at or above the ankle) within 4&#xD;
             weeks of start of treatment&#xD;
&#xD;
          -  Patient who received blood transfusions during the previous 4 weeks (to exclude the&#xD;
             potential of non-autologous ACPs in the harvested blood).&#xD;
&#xD;
          -  Inability to communicate (that may interfere with the clinical evaluation of the&#xD;
             patient)&#xD;
&#xD;
          -  Major operation during the preceding 3 months&#xD;
&#xD;
          -  Myocardial infarction or brain infarction or uncontrolled myocardial ischemia or&#xD;
             persistent severe heart failure (EF&lt; 25 %) during the preceding 3 months&#xD;
&#xD;
          -  Significant valvular disease or after valve replacement during the preceding 3 months&#xD;
&#xD;
          -  After heart transplantation&#xD;
&#xD;
          -  Severe cardiomyopathy (EF &lt; 25 %)&#xD;
&#xD;
          -  Renal failure (creatinine &gt; 2 mg/dl )&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Anemia (lower than 11mg/dl.hemoglobin for female and lower than 12 mg/dl for male)&#xD;
&#xD;
          -  Abnormal coagulation tests [platelets, PT (INR), PTT]&#xD;
&#xD;
          -  Stroke within the preceding 3 years&#xD;
&#xD;
          -  Malignancy within the preceding 3 years&#xD;
&#xD;
          -  Concurrent chronic or acute infectious disease&#xD;
&#xD;
          -  Severe concurrent medical disease (e.g., septicemia, HIV-1,2/HBV/HCV infections,&#xD;
             poorly controlled insulin-dependent diabetes mellitus ; HBA1c &gt;8 % and proliferative&#xD;
             retinopathy , systemic lupus erythematosus, multiple sclerosis, amyotrophic lateral&#xD;
             sclerosis)&#xD;
&#xD;
          -  Chronic immunomodulating or cytotoxic drugs treatment&#xD;
&#xD;
          -  Patients who have rectal temp. above 38.40C for 2 consecutive days&#xD;
&#xD;
          -  Patient unlikely to be available for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pramook Mutirangura, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular Surgery Unit,Department of Surgery,Faculty of Medicine Siriraj Hospital,Mahidol University,BKK,Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Valentin Fulga</name>
      <address>
        <city>Tel viv</city>
        <state>P.O.B.4049,Ness Ziona</state>
        <zip>74410</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>August 30, 2007</last_update_submitted>
  <last_update_submitted_qc>August 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2007</last_update_posted>
  <keyword>Stem cells</keyword>
  <keyword>Rest pain</keyword>
  <keyword>claudication</keyword>
  <keyword>chronic ischemic or non-healing ulcers</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>no-option cases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

